[1]
|
Prakken, B., Albani, S. and Martini, A. (2011) Juvenile Idiopathic Arthritis. The Lancet, 377, 2138-2149.
https://doi.org/10.1016/S0140-6736(11)60244-4
|
[2]
|
Hinze, C., Gohar, F. and Foell, D. (2015) Management of Juvenile Idiopathic Arthritis: Hitting the Target. Nature Reviews Rheumatology, 11, 290-300. https://doi.org/10.1038/nrrheum.2014.212
|
[3]
|
Ravelli, A., Consolaro, A., Horneff, G., Laxer, R.M., Lovell, D.J., Wulffraat, N.M., Akikusa, J.D., Al-Mayouf, S.M., Antón, J., Avcin, T., et al. (2018) Treating Juvenile Idiopathic Arthri-tis to Target: Recommendations of an International Task Force. Annals of the Rheumatic Diseases, 2018, Article ID: 213030.
https://doi.org/10.1136/annrheumdis-2018-213030
|
[4]
|
Foell, D., Wittkowski, H., Hammerschmidt, I., Wulffraat, N., Schmeling, H., Frosch, M., Horneff, G., Kuis, W., Sorg, C. and Roth, J. (2004) Monitoring Neutrophil Activation in Juvenile Rheumatoid Arthritis by S100A12 Serum Concentrations. Arthritis & Rheumatism, 50, 1286-1295. https://doi.org/10.1002/art.20125
|
[5]
|
Bobek, D., Grčević, D., Kovačić, N., Lukić, I.K. and Jelušić, M. (2014) The Presence of High Mobility Group Box-1 and Soluble Receptor for Advanced Glycation End-Products in Juvenile Idio-pathic Arthritis and Juvenile Systemic Lupus Erythematosus. Pediatric Rheumatology, 12, Article No. 50. https://doi.org/10.1186/1546-0096-12-50
|
[6]
|
Novick, D., Kim, S., Kaplanski, G. and Dinarello, C.A. (2013) In-terleukin-18, More than a Th1 Cytokine. Seminars in Immunology, 25, 439-448. https://doi.org/10.1016/j.smim.2013.10.014
|
[7]
|
Shimizu, M., Nakagishi, Y., Inoue, N., Mizuta, M., Ko, G., Saikawa, Y., Kubota, T., Yamasaki, Y., Takei, S. and Yachie, A. (2015) Interleukin-18 for Predicting the Development of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Clinical Immunology, 160, 277-281. https://doi.org/10.1016/j.clim.2015.06.005
|
[8]
|
Schulert, G.S., Yasin, S., Carey, B., Chalk, C., Do, T., Schapiro, A.H., Husami, A., Watts, A., Brunner, H.I., Huggins, J., et al. (2019) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis & Rheumatology, 71, 1943-1954. https://doi.org/10.1002/art.41073
|
[9]
|
Rood, J.E., Rezk, A., Pogoriler, J., Finn, L.S., Burnham, J.M., Josephson, M.B., Bar-Or, A., Behrens, E.M. and Canna, S.W. (2023) Improvement of Refractory Systemic Juvenile Idiopathic Ar-thritis-Associated Lung Disease with Single-Agent Blockade of IL-1β and IL-18. Journal of Clinical Immunology, 43, 101-108.
https://doi.org/10.1007/s10875-022-01353-y
|
[10]
|
Silva, T.A., Garlet, G.P., Lara, V.S., Martins, W., Silva, J.S. and Cunha, F.Q. (2005) Differential Expression of Chemokines and Chemokine Receptors in Inflammatory Periapical Dis-eases. Oral Microbiology and Immunology, 20, 310-316. https://doi.org/10.1111/j.1399-302X.2005.00232.x
|
[11]
|
Hasegawa, T., Venkata Suresh, V., Yahata, Y., Nakano, M., Suzuki, S., Suzuki, S., Yamada, S., Kitaura, H., Mizoguchi, I., Noiri, Y., et al. (2021) Inhibition of the CXCL9-CXCR3 Axis Suppresses the Progression of Experimental Apical Periodontitis by Blocking Macrophage Mi-gration and Activation. Scientific Reports, 11, Article No. 2613.
https://doi.org/10.1038/s41598-021-82167-7
|
[12]
|
Shimizu, M., Inoue, N., Mizuta, M., Nakagishi, Y. and Yachie, A. (2018) Characteristic Elevation of Soluble TNF Receptor II : I Ratio in Macrophage Activation Syndrome with Sys-temic Juvenile Idiopathic Arthritis. Clinical and Experimental Immunology, 191, 349-355. https://doi.org/10.1111/cei.13026
|
[13]
|
Hinze, T., Kessel, C., Hinze, C.H., Seibert, J., Gram, H. and Foell, D. (2021) A Dysregulated Interleukin-18-Interferon- γ-CXCL9 Axis Impacts Treatment Response to Canakinumab in Systemic Ju-venile Idiopathic Arthritis. Rheumatology, 60, 5165-5174. https://doi.org/10.1093/rheumatology/keab113
|
[14]
|
Wang, S., Song, R., Wang, Z., Jing, Z., Wang, S. and Ma, J. (2018) S100A8/A9 in Inflammation. Frontiers in Immunology, 9, Article No. 1298. https://doi.org/10.3389/fimmu.2018.01298
|
[15]
|
Ahn, J.G. (2020) Role of Biomarkers in Juvenile Idiopathic Arthri-tis. Journal of Rheumatic Diseases, 27, 233-240.
https://doi.org/10.4078/jrd.2020.27.4.233
|
[16]
|
Frosch, M., Ahlmann, M., Vogl, T., Wittkowski, H., Wulffraat, N., Foell, D. and Roth, J. (2009) The Myeloid-Related Proteins 8 and 14 Complex, a Novel Ligand of Toll-Like Receptor 4, and Interleukin-1β Form a Positive Feedback Mechanism in Systemic-Onset Juvenile Idiopathic Arthritis. Arthritis & Rheumatology, 60, 883-891.
https://doi.org/10.1002/art.24349
|
[17]
|
Nirmala, N., Grom, A. and Gram, H. (2014) Biomarkers in Systemic Juve-nile Idiopathic Arthritis: A Comparison with Biomarkers in Cryopyrin-Associated Periodic Syndromes. Current Opinion in Rheumatology, 26, 543-552.
https://doi.org/10.1097/BOR.0000000000000098
|
[18]
|
Miller, Y.I., Choi, S.-H., Wiesner, P., Fang, L., Harkewicz, R., Hartvigsen, K., Boullier, A., Gonen, A., Diehl, C.J., Que, X., et al. (2011) Oxidation-Specific Epitopes Are Dan-ger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. Circulation Re-search, 108, 235-248.
https://doi.org/10.1161/CIRCRESAHA.110.223875
|
[19]
|
Ometto, F., Friso, L., Astorri, D., Botsios, C., Raffeiner, B., Punzi, L. and Doria, A. (2017) Calprotectin in Rheumatic Diseases. Experimental Biology and Medicine (Maywood), 242, 859-873. https://doi.org/10.1177/1535370216681551
|
[20]
|
Romand, X., Bernardy, C., Nguyen, M.V.C., Courtier, A., Trocme, C., Clapasson, M., Paclet, M.-H., Toussaint, B., Gaudin, P. and Baillet, A. (2019) Systemic Cal-protectin and Chronic Inflammatory Rheumatic Diseases. Joint Bone Spine, 86, 691-698. https://doi.org/10.1016/j.jbspin.2019.01.003
|
[21]
|
Altobelli, E., Angeletti, P.M., Petrocelli, R., Lapergola, G., Farello, G., Cannataro, G. and Breda, L. (2021) Serum Calprotectin a Potential Biomarker in Juvenile Idiopathic Arthritis: A Meta-Analysis. Journal of Clinical Medicine, 10, Article No. 4861. https://doi.org/10.3390/jcm10214861
|
[22]
|
Holzinger, D., Frosch, M., Kastrup, A., Prince, F.H.M., Otten, M.H., Van Suijlekom-Smit, L.W.A., Cate, R., Ten. Hoppenreijs, E.P.A.H., Hansmann, S., Moncrieffe, H., et al. (2012) The Toll-Like Receptor 4 Agonist MRP8/14 Protein Complex Is a Sensitive Indicator for Disease Activity and Predicts Re-lapses in Systemic-Onset Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 71, 974-980. https://doi.org/10.1136/annrheumdis-2011-200598
|
[23]
|
Remthangpuii, F., Maheshwari, A., Gulati, S., Sharma, S., Mahto, D. and Chandra, J. (2023) Serum Calprotectin Levels in Different Subtypes of Juvenile Idiopathic Arthritis (JIA) and Its Correlation with Quantitative CRP and JADAS-27. Indian Journal of Pediatrics, 90, 1177-1181. https://doi.org/10.1007/s12098-022-04414-7
|
[24]
|
Gross, C., Belville, C., Lavergne, M., Choltus, H., Jabaudon, M., Blondonnet, R., Constantin, J.-M., Chiambaretta, F., Blanchon, L. and Sapin, V. (2020) Advanced Glycation End Prod-ucts and Receptor (RAGE) Promote Wound Healing of Human Corneal Epithelial Cells. Investigative Ophthalmology & Visual Science, 61, 14.
https://doi.org/10.1167/iovs.61.3.14
|
[25]
|
Yang, H., Wang, H. and Andersson, U. (2020) Targeting Inflammation Driven by HMGB1. Frontiers in Immunology, 11, Article No. 484. https://doi.org/10.3389/fimmu.2020.00484
|
[26]
|
Klune, J.R., Dhupar, R., Cardinal, J., Billiar, T.R. and Tsung, A. (2008) HMGB1: Endogenous Danger Signaling. Molecular Medicine, 14, 476-484. https://doi.org/10.2119/2008-00034.Klune
|
[27]
|
Xu, D., Zhang, Y., Zhang, Z.-Y. and Tang, X.-M. (2021) Associa-tion between High Mobility Group Box 1 Protein and Juvenile Idiopathic Arthritis: A Prospective Longitudinal Study. Pediatric Rheumatology, 19, Article No. 112.
https://doi.org/10.1186/s12969-021-00587-1
|
[28]
|
Ma, X., Wu, F., Xin, L., Su, G., He, F., Yang, Y., Sun, J. and Liu, Z. (2016) Differential Plasma MicroRNAs Expression in Juvenile Idiopathic Arthritis. Modern Rheumatology, 26, 224-232.
https://doi.org/10.3109/14397595.2015.1060663
|